Spondyloarthritis & psoriatic arthritis
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Authors' conclusion
Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19.
Study context
- Population
- Adults with PsO, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) with COVID-19 in the PsoProtect and Global Rheumatology Alliance physician-reported registries18.3% PsO, 45.5% PsA, 36.3% axSpA
- Participants
- 5,045 adults
- Exposure
- Characteristics associated with COVID-19 severity
- Outcome
- COVID-19 severity on a three-point ordinal scale: no hospitalisation, hospitalisation (and no death) and death
Methodological detailstwo international physician-reported registries, multivariable ordinal logistic regression
- Two international physician-reported registries
- Multivariable ordinal logistic regression
Main finding
As reported in the abstract
Odds of more severe COVID-19 (ordinal)
Odds ratio (95% CI)
Male sex
1.54(1.30–1.83)
PsOvs PsA
0.49(0.37–0.65)
TNFivs No DMARD
0.57(0.44–0.73)
IL17ivs No DMARD
0.62(0.45–0.87)
IL-23i/IL-12+23ivs No DMARD
0.67(0.45–0.98)
- Cardiovascular, respiratory, renal, metabolic and cancer comorbidities
- ORs 1.25-2.89
- Moderate/high disease activity and/or GC use vs Remission/low disease activity and no GC
- ORs 1.39-2.23
- Later pandemic time periods vs Until 15 June 2020
- ORs 0.42-0.52
Observational data: associations, not effects.
Further findings
COVID-19 outcome distribution
- Not hospitalised
- 83.6%
- Hospitalised
- 14.6%
- Died
- 1.8%
Original publication
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann Rheum Dis. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →